Table 2

Increases in Health Assessment Questionnaire Disability Index (HAQ-DI) per increase in total Sharp scores (TSS) and intermediate results

TrialTreatmentHAQ changeSDAI changefACT (HAQ/SDAI)SDAI at end pointACT-HAQHAQ at end pointDAM-HAQTotal Sharp Score at end pointHAQ/TSS
Established RA
BELIRAGlucocorticoids0.2311.30.020714.40.300.930.6338.10.0165
ATTRACTInfliximab+MTX0.5528.90.01917.70.341.090.7567.30.011
Placebo0.314.70.02029.70.611.330.7274.40.010
DE019Adalimumab+MTX0.5322.10.02418.60.450.920.4767.50.007
LEFLeflunomide0.5827.80.02121.90.460.930.4730.20.016
MTX0.6230.30.02020.40.420.880.46260.018
Salazopyrine0.5431.90.01715.90.270.780.51470.011
TEMPOEtanercept+MTX0.6823.10.02911.10.330.690.3632.40.011
Etanercept0.5522.30.02513.80.340.830.4926.50.018
MTX0.6260.02315.60.360.90.5435.30.015
Mean0.022±0.0040.53±0.130.013±0.004
Early RA
ASPIREInfliximab+MTX0.8926.40.03411.60.390.610.2211.50.019
MTX0.7322.50.03215.50.500.810.3115.40.020
ERAEtanercept0.7627.10.02817.60.490.70.2111.60.018
MTX0.7525.40.03018.40.540.680.1413.30.010
PREMIERAdalimumab0.934.50.02613.70.360.690.3321.30.016
MTX0.8835.70.02513.70.340.620.2827.40.010
Adalimumab+MTX1.0639.70.0278.70.230.410.18200.009
Mean0.029+0.0030.24±0.070.015±0.005
  • ACT-HAQ, activity-related HAQ component; ASPIRE, ‘Active-controlled Study of Patents receiving Infliximab for the treatment of RA of Early onset’; ATTRACT, ‘Anti-TNF Trial in Rheumatoid Arthritis with Concomitant Therapy’; BELIRA, ‘BEst LIfe with Rheumatoid Arthritis’; DAM-HAQ, damage-related HAQ component; ERA, ‘Early Rheumatoid Arthritis’; fACT, change in HAQ seen per change in SDAI; LEF, leflunomide; MTX, methotrexate; SDAI, Simplified Disease Activity Index; TEMPO, ‘Trial of Etanercept and Methotrexate with radiographic Patient Outcomes’; TSS, total Sharp score.